Cargando…

Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model

Botulinum neurotoxin type A (BoNT/A) cleaves SNAP-25 and interrupts the release of acetylcholine. We previously reported that BoNT/A subtype 2 (BoNT/A2) ameliorates pathologic behavior more effectively than subtype 1 (BoNT/A1) in a rat Parkinson’s disease model. Here, we further show BoNT/A2 has few...

Descripción completa

Detalles Bibliográficos
Autores principales: ITAKURA, Masanori, KOHDA, Tomoko, KUBO, Takeya, SEMI, Yuko, NISHIYAMA, Kazuhiro, AZUMA, Yasu-Taka, NAKAJIMA, Hidemitsu, KOZAKI, Shunji, TAKEUCHI, Tadayoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Veterinary Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155206/
https://www.ncbi.nlm.nih.gov/pubmed/24849052
http://dx.doi.org/10.1292/jvms.14-0184
_version_ 1782333562377207808
author ITAKURA, Masanori
KOHDA, Tomoko
KUBO, Takeya
SEMI, Yuko
NISHIYAMA, Kazuhiro
AZUMA, Yasu-Taka
NAKAJIMA, Hidemitsu
KOZAKI, Shunji
TAKEUCHI, Tadayoshi
author_facet ITAKURA, Masanori
KOHDA, Tomoko
KUBO, Takeya
SEMI, Yuko
NISHIYAMA, Kazuhiro
AZUMA, Yasu-Taka
NAKAJIMA, Hidemitsu
KOZAKI, Shunji
TAKEUCHI, Tadayoshi
author_sort ITAKURA, Masanori
collection PubMed
description Botulinum neurotoxin type A (BoNT/A) cleaves SNAP-25 and interrupts the release of acetylcholine. We previously reported that BoNT/A subtype 2 (BoNT/A2) ameliorates pathologic behavior more effectively than subtype 1 (BoNT/A1) in a rat Parkinson’s disease model. Here, we further show BoNT/A2 has fewer adverse effects than BoNT/A1. We first confirmed that intrastriatal treatments of both BoNT/As had no-effect on dopaminergic terminals in the striatum. SNAP-25 cleaved by BoNT/A2 was strictly localized to the striatum on the injected side; however, SNAP-25 cleaved by BoNT/A1 diffused contralaterally. Furthermore, treatment with BoNT/A1 caused a significant reduction in body weight, while BoNT/A2 treatment did not. These results suggest that BoNT/A2 is more beneficial for clinical application against Parkinson’s disease than BoNT/A1.
format Online
Article
Text
id pubmed-4155206
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher The Japanese Society of Veterinary Science
record_format MEDLINE/PubMed
spelling pubmed-41552062014-09-05 Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model ITAKURA, Masanori KOHDA, Tomoko KUBO, Takeya SEMI, Yuko NISHIYAMA, Kazuhiro AZUMA, Yasu-Taka NAKAJIMA, Hidemitsu KOZAKI, Shunji TAKEUCHI, Tadayoshi J Vet Med Sci Pharmacology Botulinum neurotoxin type A (BoNT/A) cleaves SNAP-25 and interrupts the release of acetylcholine. We previously reported that BoNT/A subtype 2 (BoNT/A2) ameliorates pathologic behavior more effectively than subtype 1 (BoNT/A1) in a rat Parkinson’s disease model. Here, we further show BoNT/A2 has fewer adverse effects than BoNT/A1. We first confirmed that intrastriatal treatments of both BoNT/As had no-effect on dopaminergic terminals in the striatum. SNAP-25 cleaved by BoNT/A2 was strictly localized to the striatum on the injected side; however, SNAP-25 cleaved by BoNT/A1 diffused contralaterally. Furthermore, treatment with BoNT/A1 caused a significant reduction in body weight, while BoNT/A2 treatment did not. These results suggest that BoNT/A2 is more beneficial for clinical application against Parkinson’s disease than BoNT/A1. The Japanese Society of Veterinary Science 2014-05-21 2014-08 /pmc/articles/PMC4155206/ /pubmed/24849052 http://dx.doi.org/10.1292/jvms.14-0184 Text en ©2014 The Japanese Society of Veterinary Science http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License.
spellingShingle Pharmacology
ITAKURA, Masanori
KOHDA, Tomoko
KUBO, Takeya
SEMI, Yuko
NISHIYAMA, Kazuhiro
AZUMA, Yasu-Taka
NAKAJIMA, Hidemitsu
KOZAKI, Shunji
TAKEUCHI, Tadayoshi
Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model
title Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model
title_full Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model
title_fullStr Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model
title_full_unstemmed Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model
title_short Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model
title_sort botulinum neurotoxin type a subtype 2 confers greater safety than subtype 1 in a rat parkinson’s disease model
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155206/
https://www.ncbi.nlm.nih.gov/pubmed/24849052
http://dx.doi.org/10.1292/jvms.14-0184
work_keys_str_mv AT itakuramasanori botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel
AT kohdatomoko botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel
AT kubotakeya botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel
AT semiyuko botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel
AT nishiyamakazuhiro botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel
AT azumayasutaka botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel
AT nakajimahidemitsu botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel
AT kozakishunji botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel
AT takeuchitadayoshi botulinumneurotoxintypeasubtype2confersgreatersafetythansubtype1inaratparkinsonsdiseasemodel